Goldman Sachs Maintains Neutral on Moderna, Raises Price Target to $120

Benzinga · 1d ago
Goldman Sachs analyst Salveen Richter maintains Moderna (NASDAQ:MRNA) with a Neutral and raises the price target from $67 to $120.